Tag : NASDAQ GWPH

Current News Market Watch Uncategorized

GW Pharma to Raise $300M Via Public Offering

Editor
GW Pharmaceuticals plc (NASDAQ: GWPH) announced this morning that the company’s wholly owned subsidiary, Greenwich Biosciences, plans to raise $300 million dollars via the selling GW Pharma’s common shares on the NASDAQ Global Market. The company is planning to offer the underwriters an additional 30-day option to purchase an additional $45...
Politics

DEA Gives CBD Derived Pharmaceutical, Epidiolex, Approval as a Schedule V Drug

Editor
The Drug Enforcement Administration (DEA) has given the Cannabidiol (CBD) derived pharmaceutical product, Epidiolex, a reported Schedule V status. The newly approved drug is an oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The CBD product Epidiolex is derived from the cannabis...
Current News Market Watch Uncategorized

FDA Approves GW Pharma’s CBD Derived Epidiolex to Treat Epilepsy

Editor
The United States Food & Drugs Administration (FDA) has officially approved GW Pharmaceuticals’ (NASDAQ: GWPH) Cannabidiol (CBD) derived medication called Epidiolex. The newly approved drug is a oral solution that is used for the reduction of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome. The new CBD derived pharmaceutical will be...
Current News Market Watch Uncategorized

GW Pharmaceuticals CBD Based Drug Could Receive FDA Approval Soon

Editor
WASHINGTON (AP) — A medicine made from the marijuana plant moved one step closer to U.S. approval Thursday after federal health advisers endorsed it for the treatment of severe seizures in children with epilepsy. If the Food and Drug Administration follows the group’s recommendation, GW Pharmaceuticals’ syrup would become the...
Current News Health

GW Pharma’s New Compound GWP42006 Fails Initial Trial Testing

Editor
On February 21, 2018 GW Pharmaceuticals PLC (Nasdaq:GWPH) (“GW,”) announced that a Phase 2a proof of concept study of a pipeline compound GWP42006 in adult patients with focal seizures did not meet its primary endpoint.  The trial was conducted outside the United States, primarily in Eastern Europe.  In the trial’s...